• UCLA Health
  • myUCLAhealth
  • School of Medicine
UCLA Obstetrics and Gynecology

UCLA Obstetrics and Gynecology

UCLA Obstetrics and Gynecology
  • About Us
    • Chair's Welcome
    • Contact Us
    • Giving
    • Job Listings
    • News
    • Webinars
  • Clinical Programs
    • Chronic Pelvic Pain Program
    • Family Planning
    • Fertility and Reproductive Health Center
    • Fibroid Treatment Program
    • Gynecologic Oncology
    • Gynecology
    • Labor and Delivery
    • Maternal Fetal Medicine
    • Nurse Midwives
    • Minimally Invasive & Robotic Surgery
    • Obstetrics
    • Women's Pelvic Health
  • Conditions Treated
    • Cervical Cancer
    • Cervical Insufficiency
    • Congenital Abnormalities
    • Endometriosis
    • Fibroids
    • Hirsutism
    • Infertility
    • Menopause
    • Ovarian Fallopian Tube and Primary Peritoneal Cancer
    • Polycystic Ovary Syndrome (PCOS)
    • Pregnancy
    • Premenstrual Syndrome (PMS)
    • Recurrent Pregnancy Loss
    • Reproductive Surgery
    • Sexually-transmitted Diseases
    • Urinary Tract Infection
    • Uterine / Endometrial Cancer
    • Vaginal Yeast Infection
    • Vulvar and Vaginal Cancer
    • Vulvodynia
  • For Patients
    • Coronavirus
    • Patient Stories
    • myUCLAhealth
    • Appointments
    • Clinical Updates
    • FAQs
    • Find a Doctor
    • First Visit
    • Health Plans
    • Locations
    • Medical Records
    • Patient Videos
    • Physicians Update
    • Pregnancy
    • Prescription Refill
    • Resources
    • Vital Signs Newsletters
    • Webinars
  • Clinical Trials
  • Research
    • Yalda Afshar MD PhD Lab
    • Sandra Orsulic PhD Lab
    • Women's Reproductive Health Research Program
  • Education
    • Residency
    • Fellowship Programs
    • Housestaff Roster 2020-21
    • Calendar of Events
    • Grand Rounds and Conferences
    • Medical Students
    • Aerial Tour: Why Choose UCLA?
    • Contact Academic Office
  • Our Expert Team
    • Appointment Request
    • Chronic Pelvic Pain
    • Family Planning
    • Fertility & Reproductive Health
    • Fibroid Treatment
    • Gynecologic Oncology
    • Gynecology
    • Minimally Invasive & Robotic Surgery
    • Nurse Midwives
    • Obstetrics
    • Maternal Fetal Medicine
    • Women's Pelvic Health
  • UCLA Health
  • myUCLAhealth
  • School of Medicine

UCLA Obstetrics and Gynecology

Clinical Trials

  1. Home
  2. Clinical Trials
  3. Testing the Addition of Pembrolizumab to Paclitaxel and Carboplatin for Endometrial Cancer

Testing the Addition of Pembrolizumab to Paclitaxel and Carboplatin for Endometrial Cancer

Share this

Testing the Addition of Pembrolizumab to Paclitaxel and Carboplatin for Endometrial Cancer

This Phase III research study is designed to discover whether the addition of pembrolizumab, a new immunotherapy drug, to the usual combination of chemotherapy drugs (paclitaxel and carboplatin) can lower the chance of your endometrial cancer growing or spreading. Because the study includes a placebo, patients will be randomly assigned to receive paclitaxel plus carboplatin plus pembrolizumab or paclitaxel plus carboplatin plus placebo. Pembrolizumab, is already approved by the FDA for use in several other types of cancer (e.g. melanoma, lung cancer, kidney cancer, bladdercancer, head and neck cancers and other cancers). This study, led by Dr. Joshua Cohen and associates from UCLA Department of Obstetrics and Gynecology, is intended to determine if the addition of pembrolizumab to the usual treatment for endometrial cancer could shrink or stabilize the cancer being treated.

Participants must meet the following criteria:

  1. Female
  2. Age 18+
  3. Willingness to provide Informed Consent
  4. Endometrial cancer with known MMR IHC status from institutional testing placed under one of the following:
    • Measurable stage III
    • Measurable stage IVA
    • Measurable OR Non-Measurable stage IVB
    • Measurable OR Non-Measurable Recurrent

If you've answered yes to all of the above questions, please
Email: obgynresearch@mednet.ucla.edu or Call: 310-794-9652.

 Patients will be stratified into 2 separate arms upon randomization:

  1. Arm 1: Paclitaxel and Carboplatin + Placebo
  2. Arm 2: Paclitaxel and Carboplatin + Pembrolizumab

Note: Everyone in the study will get paclitaxel and carboplatin with pembrolizumab or paclitaxel and carboplatin with a placebo for four and a half months, followed by pembrolizumab or a placebo for up to two years.

All participants enrolled in the study will undergo the following:

  • Physical Exams
  • Blood Sample Collections
  • Thyroid Testing
  • MMR IHC testing of tumor tissue
  • Questionnaires
  • CT Tumor Assessments

Once in the study, during the 1st visit, participants will be randomized (like drawing numbers from a hat) to one of the 2 treatment groups (paclitaxel and carboplatin + placebo or paclitaxel and carboplatin + pembrolizumab). As this is a placebo-controlled study, please note that you may receive inactive medications.

UCLA Protocol ID: IRB# 19-001886.

Please call (310) 794-9652 to learn more. In order to protect your privacy, please do not include any personal health information if you choose to e-mail us.
Learn more at UCLAHealth Clinical Trials >

Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest
UCLA Health hospitals ranked best hospitals by U.S. News & World Report
  • UCLA Health
  • Find a Doctor
  • School of Medicine
  • School of Nursing
  • UCLA Campus
  • Directory
  • Newsroom
  • Subscribe
  • Patient Stories
  • Giving
  • Careers
  • Volunteer
  • International Services
  • Privacy Practices
  • Nondiscrimination
  • Billing
  • Health Plans
  • Emergency
  • Report Broken Links
  • Terms of Use
  • 1-310-825-2631
  • Maps & Directions
  • Contact Us
  • Your Feedback
  • Report Misconduct
  • Get Social
  • Sitemap
Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest